Figure 1.
Short-interval opioid treatment using an optimized infusion center pain-management plan leads to equivalent reduction in patient-reported pain scores with significantly improved opioid usage, fewer ED referrals, and decreased visit length. (A) Details of standard-interval vs short-interval opioid treatment plans. (B) Patient-reported pain scores upon presentation and OEC discharge for patients receiving both standard- and short-interval therapy. Pain is reported on a scale from 1 (minimal pain) to 10 (maximal pain). (C) Mean improvement in pain score for patients receiving both standard- and short-interval therapy. P = NS by Wilcoxon matched-pairs signed rank test. (D) Total opioids administered (IV plus oral opioids, measured as MME) in patients receiving standard- and short-interval treatments. ∗∗P < .01 by Student t test. (E) Outpatient treatment failures in patients receiving standard- or short-interval treatment as measured by the number of ED visits within 72 hours of discharge from the infusion visit. ∗∗∗P < .001 by Student t test. (F) Total length of outpatient infusion visits for patients receiving standard- or short-interval treatment. ∗P < .05 by Student t test. NS, not significant; NSAID, nonsteroidal anti-inflammatory drug; SCD, sickle cell disease.

Short-interval opioid treatment using an optimized infusion center pain-management plan leads to equivalent reduction in patient-reported pain scores with significantly improved opioid usage, fewer ED referrals, and decreased visit length. (A) Details of standard-interval vs short-interval opioid treatment plans. (B) Patient-reported pain scores upon presentation and OEC discharge for patients receiving both standard- and short-interval therapy. Pain is reported on a scale from 1 (minimal pain) to 10 (maximal pain). (C) Mean improvement in pain score for patients receiving both standard- and short-interval therapy. P = NS by Wilcoxon matched-pairs signed rank test. (D) Total opioids administered (IV plus oral opioids, measured as MME) in patients receiving standard- and short-interval treatments. ∗∗P < .01 by Student t test. (E) Outpatient treatment failures in patients receiving standard- or short-interval treatment as measured by the number of ED visits within 72 hours of discharge from the infusion visit. ∗∗∗P < .001 by Student t test. (F) Total length of outpatient infusion visits for patients receiving standard- or short-interval treatment. ∗P < .05 by Student t test. NS, not significant; NSAID, nonsteroidal anti-inflammatory drug; SCD, sickle cell disease.

Close Modal

or Create an Account

Close Modal
Close Modal